Conserved signatures of the canine faecal microbiome are associated with metronidazole treatment and recovery

Autor: Zoe V. Marshall-Jones, Krusha V. Patel, Juan Castillo-Fernandez, Zoe N. Lonsdale, Richard Haydock, Ruth Staunton, Gregory C. A. Amos, Phillip Watson

Publikováno v: Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)

Abstract Antibiotic resistance is recognised as one of the biggest global threats to human and animal health. Understanding the influence of antibiotics on the canine microbiome is important to know the potential mid-to-long term effects on dysbiosis

Externí odkaz: https://doaj.org/article/506d4b1b413544e691707c9470df7888

Novel therapeutic approaches for pediatric diencephalic tumors: improving functional outcomes

Autor: Julia V. Cockle, Elizabeth A. Corley, Bassel Zebian, Samantha Hettige, Sucheta J. Vaidya, Paola Angelini, Joanna Stone, R Jane Leitch, Assunta Albanese, Henry C. Mandeville, Fernando Carceller, Lynley V. Marshall

Publikováno v: Frontiers in Oncology, Vol 13 (2023)

Pediatric diencephalic tumors represent a histopathologically and molecularly diverse group of neoplasms arising in the central part of the brain and involving eloquent structures, including the hypothalamic-pituitary axis (HPA), optic pathway, thala

Externí odkaz: https://doaj.org/article/230517706a4040d5937a2e3f7c98238e

Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab

Autor: Arash Nabbi, Arnavaz Danesh, Osvaldo Espin-Garcia, Stephanie Pedersen, Johanna Wellum, Lingyan Helen Fu, Joseph N. Paulson, Birgit Geoerger, Lynley V. Marshall, Tanya Trippett, Gianluca Rossato, Trevor J. Pugh, Katherine E. Hutchinson

Publikováno v: Nature Cancer. 4:502-515

We report herein an exploratory biomarker analysis of refractory tumors collected from pediatric patients before atezolizumab therapy (iMATRIX-atezolizumab, NCT02541604). Elevated levels of CD8+ T cells and PD-L1 were associated with progression-free

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc5ba6c3574e1caf0bfef146d2241f38
https://doi.org/10.1038/s43018-023-00534-x

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial

Autor: Birgit Geoerger, Lynley V. Marshall, Karsten Nysom, Guy Makin, Eric Bouffet, Anne-Sophie Defachelles, Loredana Amoroso, Isabelle Aerts, Pierre Leblond, Paulette Barahona, Kim Van-Vlerken, Eric Fu, Flavio Solca, Robert M. Lorence, David S. Ziegler

Publikováno v: Geoerger, B, Marshall, L V, Nysom, K, Makin, G, Bouffet, E, Defachelles, A, Amoroso, L, Aerts, I, Leblond, P, Barahona, P, Van-Vlerken, K, Fu, E, Solca, F, Lorence, R M & Ziegler, D S 2023, ' Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial ', European Journal of Cancer, vol. 188, pp. 8-19 . https://doi.org/10.1016/j.ejca.2023.04.007

AimThis phase I/expansion study assessed the safety, pharmacokinetics and preliminary antitumor activity of afatinib in paediatric patients with cancer.MethodsThe dose-finding part enroled patients (2–150); HER2 membrane staining (H-score>0). The p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84e7ec8128779224aaf622e0bc13f9e5
https://research.manchester.ac.uk/en/publications/dd144159-5cb1-4625-acc3-ccddb47135db